Literature DB >> 6361256

Receptor binding sites of hypoglycemic sulfonylureas and related [(acylamino)alkyl]benzoic acids.

G R Brown, A J Foubister.   

Abstract

The blood glucose level lowering activity of [(acylamino)ethyl]benzoic acids, such as p-[2-(5-chloro-2-methoxy-benzamido)ethyl]benzoic acid (HB699, 2), is discussed in terms of binding at putative insulin-releasing receptor sites of pancreatic beta cells. The hypoglycemic potencies found for synthetic analogues of 2 indicate that high hypoglycemic activity is only found when a carboxyl group or a group that is readily oxidized to carboxyl in vivo, such as methyl, is attached to the aromatic ring of the phenethyl group. It is proposed that this carboxyl group is able to bind at the same receptor site as the SO2NHCONH group of the sulfonylurea drugs, such as tolbutamide (3). The role of the benzamide group in 2 was attributed to protein binding.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361256     DOI: 10.1021/jm00367a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  12 in total

1.  Mechanism of the stimulation of insulin release in vitro by HB 699, a benzoic acid derivative similar to the non-sulphonylurea moiety of glibenclamide.

Authors:  M G Garrino; W Schmeer; M Nenquin; H P Meissner; J C Henquin
Journal:  Diabetologia       Date:  1985-09       Impact factor: 10.122

2.  Location of the sulphonylurea receptor at the cytoplasmic face of the beta-cell membrane.

Authors:  M Schwanstecher; C Schwanstecher; C Dickel; F Chudziak; A Moshiri; U Panten
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 3.  Interaction of sulfonylurea with the pancreatic B-cell.

Authors:  E Gylfe; B Hellman; J Sehlin; B Täljedal
Journal:  Experientia       Date:  1984-10-15

4.  Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl- channels by non-sulphonylurea hypoglycaemic agents.

Authors:  Z Cai; K A Lansdell; D N Sheppard
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.

Authors:  M Meyer; F Chudziak; C Schwanstecher; M Schwanstecher; U Panten
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

6.  Relationships between the Na(+)/K(+) pump and ATP and ADP content in mouse pancreatic islets: effects of meglitinide and glibenclamide.

Authors:  A Elmi; L A Idahl; J Sehlin
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

7.  Synthesis, characterization, antioxidant activity and DNA-binding studies of three rare earth (III) complexes with 1-(4-aminoantipyrine)-3-tosylurea ligand.

Authors:  Pin-xian Xi; Zhi-hong Xu; Xiao-hui Liu; Feng-juan Chen; Zheng-zhi Zeng; Xiao-wen Zhang; Ying Liu
Journal:  J Fluoresc       Date:  2008-06-04       Impact factor: 2.217

8.  Effects of sulphonylureas and diazoxide on insulin secretion and nucleotide-sensitive channels in an insulin-secreting cell line.

Authors:  N C Sturgess; R Z Kozlowski; C A Carrington; C N Hales; M L Ashford
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

9.  Mg(2+)-dependent inhibition of KATP by sulphonylureas in CRI-G1 insulin-secreting cells.

Authors:  K Lee; S E Ozanne; C N Hales; M L Ashford
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

Review 10.  Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.

Authors:  A Melander; P O Bitzén; O Faber; L Groop
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.